Karyopharm Therapeutics (KPTI) EPS (Basic) (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly EPS (Basic) came in at $12015.3 in Q4 2025, up 113.78% YoY from $5620.3 in Q4 2024, and up 414.43% on a QoQ basis from -$3821.3 in Q3 2025.
Karyopharm Therapeutics (KPTI) EPS (Basic) (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of EPS (Basic) data on file, last reported at $12015.3 in Q4 2025.
- Quarterly EPS (Basic) rose 113.78% year-over-year to $12015.3 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3433.6 (up 121194.31% YoY) and the FY2025 annual result came in at $3433.6, up 121194.31% from the prior year.
- EPS (Basic) grew to $12015.3 in Q4 2025, from -$3821.3 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of $12015.3 in Q4 2025 to a low of -$11556.8 in Q1 2021.
- A 5-year average of -$436.44 and a median of -$7.01 in 2022 frame the typical range for EPS (Basic).
- Annual changes were most pronounced in 2024 — EPS (Basic) jumped 42197.63% — and 2025, when it tumbled 146662.92%.
- Tracing KPTI's EPS (Basic) over 5 years: stood at $7.72 in 2021, then sank by 193.56% to -$7.22 in 2022, then jumped by 283.95% to $13.29 in 2023, then jumped by 42197.63% to $5620.3 in 2024, then jumped by 113.78% to $12015.3 in 2025.
- The last three EPS (Basic) figures came in at $12015.3 (Q4 2025), -$3821.3 (Q3 2025), and -$4321.6 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.23 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.06 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.18 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -0.72 |
| 10 | Karyopharm Therapeutics | 53.25 Mn | 53.25 Mn | 32.35 Mn | -2.32 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.13 |
| Dec 31, 2025 | 12,015.27 |
| Sep 30, 2025 | -3,821.32 |
| Jun 30, 2025 | -4,321.58 |
| Mar 31, 2025 | -2,770.01 |
| Dec 31, 2024 | 5,620.31 |
| Sep 30, 2024 | -3,848.33 |
| Jun 30, 2024 | 2.95 |
| Mar 31, 2024 | -4.85 |
| Dec 31, 2023 | 13.29 |
| Sep 30, 2023 | -4.52 |
| Jun 30, 2023 | -4.29 |
| Mar 31, 2023 | -4.51 |
| Dec 31, 2022 | -7.22 |
| Sep 30, 2022 | -6.79 |
| Jun 30, 2022 | -9.24 |
| Mar 31, 2022 | -8.01 |
| Dec 31, 2021 | 7.72 |
| Sep 30, 2021 | -10.30 |
| Jun 30, 2021 | -10.69 |